Судебно-фармацевтическое изучение рисков при обращении психоактивных веществ в составе анорексигенных препаратов

Статья в Elpub

Рецепт. 2018; : 798-806

Судебно-фармацевтическое изучение рисков при обращении психоактивных веществ в составе анорексигенных препаратов

Шаповалов В. В., Шаповалова В. А., Негрецкий С. Н., Радионова В. А., Зброжек С. И., Шаповалов В. В.

Аннотация

На основании обзора научной литературы доказана небезопасность злоупотребления препаратами анорексигенного действия на примере препаратов для похудения с психоактивнымвеществом сибутрамин и орлистат. Определен ассортимент препаратов с психоактивным веществом сибутрамин, находившихся в обращении на фармацевтическом рынке Украины до 2014 года. Согласно действующего законодательства определен режим контроля препаратов с психоактивным веществом сибутрамин в аптечных учреждениях. Приведены примеры из судебно-фармацевтической практики относительно нелегального оборота препаратов с сибутрамином. Проанализирован ассортимент зарегистрированных в Украине лекарственных средств с международным непатентованным названием оrlistat. Исследован их режим контроля в аптечных учреждениях. В результате судебно-фармацевтического изучения оборота психоактивных веществ в составе анорексигенных препаратов выяснены риски при обращении анорексигенных препаратов.

Список литературы

1. Shapovalov V. (Jr.), Gudzenko A., Shapovalova V., Osyntseva A., Shapovalov V. (2017) Forensic and pharmaceutical study of the presence of a causal link between the degree of alcohol abuse and qualification level of the respondents. Pharmacia, 64 (3), рр. 31-39.

2. Shapovalov V. (Jr.), Gudzenko А., Komar L., Butko А., Shapovalova V., Shapovalov V. (2017) Concerning the importance of forensic and pharmaceutical researches to improve patients’ accessibility to medicines. Pharmacia, 65 (2), рр. 23-29.

3. Shapovalov V.V. (jr.), Shapovalov V.V., Zbrozhek S.I., Shapovalova V.A., Komar L.A. (2015) Forensic and pharmaceutical characteristics of the offenses in the sphere of the circulation of drugs and substances of various classification and legal groups. Pharmacy of Kazakhstan, 3 (166), рр. 46-50.

4. Shapovalova V.A., Sosin I.K., Shapovalov V.V. (2004) Pharmaceutical law in narcology. Fact, Kharkiv, 800 p.

5. Radionova V.A., Shapovalov V.V. (Jr.), Shapovalova V.A., Shapovalov V.V., Kapielnikova I.V. (2015) Forensic and pharmaceutical study of women drug addiction: causal links between the circulation of the psychoactive substances, disease and drug-related crimes. Scientific bulletins of Belgorod state university (Medicine, Pharmacy), 29, рр. 124-130.

6. Radionova V.О., Zbrozhek S.I., Shapovalova V.О., Shapovalov V.V. (2016) Study of the availability in circulation of medicines for women with addictive health disorders. Sciences of Europe, 10 (10), рр. 50-58.

7. Slobozhansky chytannya. Medical and pharmaceutical law of Ukraine: materials of the XІ Scientific and practical conference with international specialists’ participation. Kharkiv, Ukraine, 13-14 November 2014. Eds. V.V. Shapovalov, V.V. Shapovalov (Jr.), V.O. Shapovalova, Yu.V. Vasina, 374 p.

8. Slobozhansky chytannya. Medical and pharmaceutical law of Ukraine: materials of the XІІ Scientific and practical conference with international specialists’ participation. Kharkiv, Ukraine, 19-20 November 2015. Eds. V.V. Shapovalov, V.V. Shapovalov (Jr.), V.O. Shapovalova, O.V. Rohozhnykova, 198 р.

9. Mikhailov B.V., Martynenko A.O., Sarvik I.M., Markova M.V. (2000) Theoretical problems of treatment and prevention of dependence on psychoactive substances. Archive of psychiatry, 3-4 (22-23), рр. 9-10.

10. Ministry of healthcare of Ukraine official site. URL: http://mozdocs.kiev.ua/liki.php?name=Sibutramine&la ng=2&manufacturer=&category=0&likform=0&pokaz=&atcode=&go=%CF%EE%F8%F3%EA&nav=1&hf=1

11. &am=[Accessed on: 11 June 2018].

12. In Odessa, covered an online store, selling“wrong” drugs. URL: http://dumskaya.net/news/V-Odesse-nakryli- internet-magazin-prodavshij-nep-014753 [Accessed on: 16.09.2011].

13. Müller D., Weinmann W., Hermanns-Clausen M. (2009) Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int., 106 (13), рр. 218-22. URL: http://www.ncbi.nlm.nih. gov/pubmed/19471631.

14. The use of “Rozeqlikazon” and “Sibutramin” drugs is prohibited in Azerbaijan. URL: http://ru.apa.az/novosti- azerbaydjana/sotsium/v-azerbajdzhane-zapresheno-ispolzovanie-preparatov-rozeqlikazon-i-sibutramin-. html [Accessed on: 01.12.2011].

15. Dahlin A., Beermann B. (2007) Incorrect use of orlistat and sibutramine in clinical practice. Eur. J. Clin Pharmacol, 63 (2), рр. 205-9. URL: http://www.ncbi.nlm.nih.gov/pubmed/17205321.

16. Richter W.O. (1999) How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine. MMW Fortschr Med., 141 (49-50), рр. 32-6. URL: http://www.ncbi.nlm.nih.gov/ pubmed/10726144.

17. Florentin M., Liberopoulos E., Elisaf M. (2008) Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev., 9 (4): 378-87. URL: http://www.ncbi.nlm.nih.gov/pubmed/18034790.

18. Derosa G., Cicero A., Murdolo G., Piccinni M. (2005) Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab., 7 (1): 47-55. URL: http://www. ncbi.nlm.nih.gov/pubmed/15642075.

Recipe. 2018; : 798-806

Forensic and pharmaceutical study of risks during the circulation of psychoactive substances in the composition of anorexigenic preparations

Shapovalov V. ., Shapovalova V. ., Negretsky S. ., Radionova V. ., Zbrozhek S. ., Shapovalov V. .

Abstract

Based on the review of scientific literature, the danger of misuse of anorexigenic preparations on the example of medicines for weight loss with the psychoactive substance sibutramine and orlistat is proved. Revealed, that the assortment of medicines with psychoactive substance sibutramine was in circulation in the pharmaceutical market of Ukraine until 2014. According to the current legislation, the control regime of medicines with the psychoactive substancesibutramine in pharmacy establishments is determined. The examples are given from forensic and pharmaceutical practice with regard to illegal circulation of medicines with sibutramine. The range of registered medicinal products in Ukraine with the international non-patented name Orlistat was analyzed. Their control regime was studied in pharmacy establishments. Because of forensic and pharmaceutical study of the circulation of psychoactive substances in anorexigenic medicines, the risks of the treatment of anorexigenic medicines were identified.

References

2. Shapovalov V. (Jr.), Gudzenko A., Komar L., Butko A., Shapovalova V., Shapovalov V. (2017) Concerning the importance of forensic and pharmaceutical researches to improve patients’ accessibility to medicines. Pharmacia, 65 (2), rr. 23-29.

4. Shapovalova V.A., Sosin I.K., Shapovalov V.V. (2004) Pharmaceutical law in narcology. Fact, Kharkiv, 800 p.

6. Radionova V.O., Zbrozhek S.I., Shapovalova V.O., Shapovalov V.V. (2016) Study of the availability in circulation of medicines for women with addictive health disorders. Sciences of Europe, 10 (10), rr. 50-58.

10. Ministry of healthcare of Ukraine official site. URL: http://mozdocs.kiev.ua/liki.php?name=Sibutramine&la ng=2&manufacturer=&category=0&likform=0&pokaz=&atcode=&go=%CF%EE%F8%F3%EA&nav=1&hf=1

11. &am=[Accessed on: 11 June 2018].

12. In Odessa, covered an online store, selling“wrong” drugs. URL: http://dumskaya.net/news/V-Odesse-nakryli- internet-magazin-prodavshij-nep-014753 [Accessed on: 16.09.2011].

13. Müller D., Weinmann W., Hermanns-Clausen M. (2009) Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int., 106 (13), rr. 218-22. URL: http://www.ncbi.nlm.nih. gov/pubmed/19471631.

15. Dahlin A., Beermann B. (2007) Incorrect use of orlistat and sibutramine in clinical practice. Eur. J. Clin Pharmacol, 63 (2), rr. 205-9. URL: http://www.ncbi.nlm.nih.gov/pubmed/17205321.

16. Richter W.O. (1999) How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine. MMW Fortschr Med., 141 (49-50), rr. 32-6. URL: http://www.ncbi.nlm.nih.gov/ pubmed/10726144.